Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients예방 접종을 받은 유지 혈액 투석 환자에서 SARS-CoV-2 B.1.617.2 변이체에 의한 체액 반응 및 돌발성 감염Observational Study Published on 2022-06-012022-09-11 Journal: Journal of Nephrology [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] 30-Day mortality 95% CI all-cause mortality analysed antibody B.1.617.2 BNT162b2 BNT162b2 vaccine Breakthrough COVID-19 infection Breakthrough infection caused clinical outcomes Control control group COVID-19 COVID-19 case COVID-19 infection Critical disease declining delta variant dose Effectiveness Hematological malignancies Hemodialysis Hospitalization humoral Humoral response Immunosuppression Immunosuppressive treatment Infection investigated maintenance Maintenance hemodialysis morbidity and mortality Mortality mortality rate nosocomial occur occurred Odds ratio outcome overall mortality Patient patients Pfizer-BioNTech required response to vaccination retrospective risk factor Risk factors SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 variant SARS-CoV-2 variant. SARS-CoV-2 variants significantly higher source of infection Spike protein study group Treatment vaccination Vaccine variant [DOI] 10.1007/s40620-022-01245-9 PMC 바로가기 [Article Type] Observational Study
Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies혈액암이 있는 SARS-CoV-2 BNT162b2 mRNA 백신 접종 이식 환자의 감소된 항체 및 선천적 사이토카인 변화Article Published on 2022-05-252022-09-12 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] adaptive antibodies antibody approach Beta BNT162b2 mRNA vaccination Bone marrow booster vaccination CAR-T cell change Cohort cohorts correlated COVID-19 vaccination CXCL10 cytokine cytokine response Delta described develop Effectiveness Efficacy elicited healthy hematological hematological cancer Hematological malignancies Hematological malignancy heterogeneous high risk humoral Humoral response IFN-gamma IFN-γ IL-10 IL-15 IL-7 IL-8 individual Innate innate response IP-10/CXCL10 magnitude MIP-1α mRNA naïve neutralized offer omicron Patient patient cohort Predictive priming vaccination prognostic protection Proteins recipients reduced response SARS-CoV-2 SARS-CoV-2 BNT162b2 SARS-CoV-2 bnt162b2 mRNA vaccine SARS-COV-2 infection severe disease signature response significantly lower spike systemic cytokine response the patient the Spike Transplant transplantation. vaccination Vaccine WA1 wildtype Wuhan strain [DOI] 10.3389/fimmu.2022.899972 PMC 바로가기 [Article Type] Article
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders혈액 질환 환자의 SARS-CoV-2 백신 반응 및 돌발성 감염률Multicenter Study Published on 2022-05-072022-09-11 Journal: Journal of Hematology & Oncology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] 95% confidence interval Allogeneic stem cell transplantation Analysis antibody Antibody Response Antibody titer Antibody titers Antibody Units Asymptomatic Autologous stem cell transplantation benefit binding antibody unit binding antibody units BNT162b2 Breakthrough infection Breakthrough SARS-CoV-2 infection Cell Cell therapy Clinical efficacy cohort study Complete conducted correlates of protection COVID-19 Cutoff detectable disorder disorders doses Follow-up hematological Hematological malignancies highlight immunization Immunocompromised Immunocompromised patients Immunosuppressed immunosuppressed patient immunosuppressed patients incidence incidence rate Infection Level median Moderna Moderna mRNA-1273 mortality rate Most patient Most patients multicenter multivariate logistic regression multivariate logistic regression analysis Patient Pfizer Pfizer-BioNTech Pfizer-BioNTech BNT162b2 Pneumonia Ratio SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine SARS-CoV-2 vaccines SARS-CoV-2 variants severe disease severity significantly lower Spanish stem cell Stem cell transplantation therapy vaccination vaccine. was used [DOI] 10.1186/s13045-022-01275-7 PMC 바로가기 [Article Type] Multicenter Study
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO studyB세포 악성종양에서 백신 2~3회 접종 후 SARS-CoV-2 변이체에 대한 면역 반응: UK PROSECO 연구Observational Study Published on 2022-05-012022-09-11 Journal: Nature cancer [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] anti-CD20 anti-CD20 therapy antibody Antibody Response anticancer Antigen B-cell B-cell lymphoma booster vaccination cancer treatment COVID-19 vaccine dose doses Hematological malignancies Hematological malignancy Humoral response immune response immune responses increased risk individual indolent intrinsic limitation intrinsic limitations lymphoma observational study outcome Patient populations prospective observational study receiving responses against SARS-CoV-2 variant severe COVID-19 Study design T-cell responses therapy Treatment undetectable urgency vaccination Vaccine vaccine dose [DOI] 10.1038/s43018-022-00364-3 PMC 바로가기 [Article Type] Observational Study
Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 VaccinationSARS-CoV-2 예방접종 후 혈액암 환자의 혈청전환율에 대한 치료의 영향Meta-Analysis Published on 2022-04-052022-09-12 Journal: The oncologist [Category] COVID19(2023년), SARS, 진단, [키워드] 95% confidence interval acute respiratory syndrome Anti-CD20 antibody antibody ARMS article chronic CLL CLL patient conducted Control coronavirus COVID-19 database determinants Efficacy first dose group healthy control hematologic Hematologic malignancy hematological Hematological malignancies Hematological malignancy Impact kinase literature review malignancies Meta-analysis organization Patient patient population patients treated Rate remained review risk SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine second dose seroconversion rate significant difference significantly lower subject subjects the antibody response treated vaccination Vaccine vaccine. [DOI] 10.1093/oncolo/oyac032 PMC 바로가기 [Article Type] Meta-Analysis
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert ConsensusCOVID-19 전염병 동안 혈액암 환자 관리: ESMO-EHA 학제간 전문가 합의Article Published on 2022-04-012022-09-12 Journal: ESMO open [Category] 변종, 임상, 진단, [키워드] cancer patient Care clinical decision clinical evidence Clinical management consensual Consensus consensus manuscript COVID-19 COVID-19 diagnosis COVID-19 pandemic develop European European Hematology Association expert Guidance hematological Hematological malignancies hematological malignancies. Hematological malignancy International management managing manuscript neoplasm pandemic Patient question raising reached Result Society Treatment [DOI] 10.1016/j.esmoop.2022.100403 PMC 바로가기 [Article Type] Article
Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case SeriesAnti-SARS-CoV-2 단클론항체를 포함한 SARS-CoV-2 감염 혈액병 환자의 종합 치료: 단일 센터 경험 사례 시리즈Article Published on 2022-03-262022-09-11 Journal: Current Oncology [Category] MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Administered Analysis antibody Antibody therapy B.1.1.529 B.1.617.2 bamlanivimab benefit best Cancer case sery Casirivimab clearance clinical clinical effectiveness Combination Comprehensive coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient delta variant Diagnosis Effectiveness exacerbated experience FIVE hematologic hematologic malignancies Hematologic malignancy Hematological malignancies high risk Hospitalization Imdevimab imdevimab. Including knowledge lAbel less mAbs monoclonal antibodies monoclonal antibody Mortality off-label omicron Omicron variant oxygen oxygen supplementation Patient Potential receiving reduce reduced reduction in respiratory retrospective risk SARS-CoV-2 SARS-CoV-2 clearance SARS-COV-2 infection SARS-CoV-2-infected patient Sery severe acute respiratory syndrome Coronavirus shown Sotrovimab suggested Tolerability Treatment variant [DOI] 10.3390/curroncol29040188 PMC 바로가기 [Article Type] Article
Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia이전에 항-CD20 단일클론 항체 매개 B 세포 고갈 및 만성 림프구성 백혈병이 있는 환자에서 장기간 바이러스 SARS-CoV-2 복제에 대한 성공적인 구조 치료제로서의 플리티뎁신Case Reports Published on 2022-01-102022-09-10 Journal: Journal of Hematology & Oncology [Category] SARS, 바이오마커, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 affected anti-CD20 Anti-CD20 monoclonal antibody Antiviral antiviral drug antiviral therapies antiviral therapy B cell CD19 CD20 chronic lymphocytic leukemia compassionate use coronavirus coronavirus disease Course COVID-19 COVID-19 pneumonia deficiency develop hematological Hematological malignancies Host immune Immune deficiencies Immunosuppressed Infection leukemia Lymphocytic leukemia male monoclonal monoclonal antibodies Patient Plitidepsin Pneumonia Population Prolonged viral replication resolved respiratory SARS-CoV-2 SARS-CoV-2 patient SARS-CoV-2 patients SARS-CoV-2 replication Severe COVID-19 pneumonia supplementary material Support toxicities treated Treatment treatment with anti-CD20 undetectable Viral Viral load [DOI] 10.1186/s13045-021-01220-0 PMC 바로가기 [Article Type] Case Reports
Two Doses of BNT162b2 mRNA Vaccine in Patients after Hematopoietic Stem Cell Transplantation: Humoral Response and Serological Conversion PredictorsArticle Published on 2022-01-102022-10-31 Journal: Cancers [Category] COVID-19, [키워드] addition adverse event adverse events Allogeneic allogeneic transplantation Analysis anti-SARS-CoV-2 antibody anti-SARS-CoV-2 vaccination antibody autologous B-cell BNT162b2 mRNA vaccine CNI collected Concentration conversion correlated COVID-19 COVID-19 pandemic dose Efficacy Efficacy and safety examined HCT Hematological malignancies hematopoietic hematopoietic stem cell transplantation humoral Humoral response immune response predictors immunogenic Immunosuppressive treatment inhibitor intensity knowledge lack lymphocyte subpopulation mRNA mRNA vaccine multivariate model of BNT162b2 Patient patients Post-vaccine predictor predictors remained response SARS-CoV-2 SARS-COV-2 infection searched Seroconversion serological simple STEM Stem cell transplantation Treatment Univariate analysis vaccination [DOI] 10.3390/cancers14020325 PMC 바로가기 [Article Type] Article
Vaccination for SARS-CoV-2 in Hematological Patients혈액학적 환자의 SARS-CoV-2 백신 접종Review Published on 2022-01-012022-09-11 Journal: Acta haematologica [Category] SARS, 임상, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adverse event adverse events Anti-CD20 antibodies antibody antigen receptor approach Better chimeric antigen receptor chronic lymphocytic leukemia chronic myeloid leukemia controlled trials coronavirus coronavirus disease Coronavirus disease 2019 correlation COVID-19 COVID-19 vaccine COVID-19 vaccines death demonstrated disease dose drugs effective Effectiveness evaluate excluded General population healthy subjects Hematological malignancies Hematological malignancy HM patient HM patients humoral Humoral response immune response Immunocompromised Immunocompromised patient Immunocompromised patients increased risk Infection kinase inhibitors leukemia Lymphocytic leukemia lymphoproliferative disorders mRNA vaccination mRNA vaccine Multiple myeloma Myeloma Non-Hodgkin Lymphoma non-randomized studies non-randomized study Patient patients patients with HM provided Randomized controlled trials reported respiratory response rate ruxolitinib Safe SARS-CoV-2 serology testing Seropositivity severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severe disease T-cell T-cell Response T-cell responses therapy tyrosine tyrosine kinase inhibitors vaccination Vaccinations Vaccinations. Vaccine venetoclax [DOI] 10.1159/000523753 PMC 바로가기 [Article Type] Review